2022
Metabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2022, 87-104. DOI: 10.1007/978-3-030-41683-6_51.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence
2021
Metabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2021, 1-19. DOI: 10.1007/978-3-030-37482-2_51-1.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence
2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2014
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2014, 22: 175-183. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEnd-stage liver diseaseCost-effectiveness analysisF3-F4Liver diseaseChronic hepatitis C genotype 1 patientsHepatitis C genotype 1 patientsItalian National Health System perspectiveNational Health System perspectiveResponse-guided therapyGenotype 1 patientsMETAVIR fibrosis stageHealth system perspectiveQuality-adjusted life yearsPatient selection strategiesCost-effectiveness ratioG1 patientsNaive patientsTriple therapyOnly patientsAdvanced fibrosisFuture regimensMore regimensTreatment optionsFibrosis stage
2010
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C
Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M, Benedetti A, Marchesini G. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 2010, 60: 108. PMID: 20966027, PMCID: PMC3784835, DOI: 10.1136/gut.2010.219741.Peer-Reviewed Original ResearchConceptsChronic hepatitis CFibroblast-specific protein-1Epithelial-mesenchymal transitionInsulin resistanceDuctular reactionHepatitis CHepatic fibrosisEpithelial componentOral glucose insulin sensitivityOral glucose tolerance testTertiary care academic centerEpithelial-mesenchymal transition (EMT) markersNuclear Snail expressionProspective observational studyGlucose insulin sensitivityGlucose tolerance testDegree of necroinflammationStage of fibrosisTissue repairCK7-positive cellsNecroinflammatory activityNecroinflammatory scoreAdvanced fibrosisConsecutive patientsTotal inflammation